The UK NICE’s recommendation was based on the review of 28 papers, which included 24 clinical trials. Image Credit: Smith+Nephew.

UK National Institute for Health and Care Excellence (Nice) has recommended that Smith+Nephew’s PICO single-use negative pressure wound therapy (sNPWT) should be considered for closing surgical incisions in patients who are at high risk of surgical site infections.

The UK agency found that the patients with a high risk of surgical site infections had better outcomes with similar overall costs using sNPWT when compared to standard dressings. The guidance was reaffirmed in NICE’s guidance titled ‘Medical Technology Guideline 43 PICO negative pressure wound dressings for closed surgical incisions’.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

NICE’s recommendation was based on the review of 28 papers, which included 24 clinical trials. The review found that sNPWT use was associated with fewer surgical site infections and seroma (localised accumulation of fluid following surgery) when compared with standard wound dressings. While sNPWT was as cost-effective as the standard wound dressings in most cases, it provided cost savings for some surgeries including colorectal, cardiothoracic and vascular surgeries.

sNPWT uses an airlock technology to deliver a negative pressure wound therapy across a surgical incision and the surrounding zone of injury. The negative pressure works by applying sub-atmospheric pressure to help reduce inflammation, fluid, wound tension, and infection, thereby, preventing common surgical complications including surgical site infections and wound dehiscence or wound separation.

According to GlobalData analysis, the global wound care management market was worth approximately  $30bn in 2023 and is expected to reach nearly $38bn by 2030. UK is a big market for wound management, with approximately 2.3m procedures performed using advanced wound dressings in the UK, as per GlobalData analysis.

See Also:

GlobalData is the parent company of Clinical Trials Arena.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Another approach to wound management is the use of a fish-skin graft product. Kerecis has a range of fish-skin products, which use the skin of the North Atlantic cod. The company’s new product, Shield Standard, has a borderless contact layer made of silicone to protect the fish skin that acts as an adhesive to maintain a moist wound healing environment.

Earlier this week, Smith+Nephew launched a home-based negative pressure wound therapy, Renasys Edge, in the US. The system is used to treat chronic wounds and can be worn without interfering with daily activities.